Last updated: 11/07/2018 04:59:17
Validation study of multiple probe compounds for drug interaction evaluation
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Cytochrome P450 Probe Drugs in Healthy Adult Subjects
Trial description: The purpose of this study is to identify and validate a probe cocktail for use in future drug-drug interaction studies. Cytochrome P450 enzymes and transport proteins play important roles in the disposition of drugs. Changes in the activity of these pathways can be assessed using probe drugs selected on the basis of their metabolic or transport pathway. This will be a two part study with the same subjects participating in both parts to decrease variability in data. The purpose of Part 1 is to identify a set of probe drugs (‘cocktail’) which do not interact with one another; groups of healthy volunteers will receive 7 probe drugs individually and as a combination of the 7 drugs given together as a cocktail. Part 2 will assess the performance of the probe cocktail using three known inhibitors (validation). The inhibitors plus probe cocktail will evaluate the ability of the newly established cocktail to accurately quantify metabolizing enzyme or transporter inhibition, representing a fundamental advance in probe cocktail validation and utility for drug development.
Primary purpose:
Basic Science
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Pharmacokinetic parameters
Timeframe: life of study
Secondary outcomes:
To assess the safety and tolerability of co-administration of probe drugs
Timeframe: life of study
Interventions:
Drug: Caffeine
Drug: Rosiglitazone
Drug: Flurbiprofen
Drug: Omeprazole
Drug: Dextromethorphan
Drug: Midazolam
Drug: Rosuvastatin
Drug: Ketoconazole
Drug: Fluconazole
Drug: Rifampin
Enrollment:
87
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
A. Rizwan, K. Connelly, I-J. Jang , J-G. Shin, J. Morrill, D. Ouellet, K. Adkison, J. Chism, S. Shearn, C. Matheny, J. W. Polli, F. Hoke, G. Derimanov.Validation of a Seven-Probe Cytochrome P450/Transporter Cocktail Using Known Inhibitors.American Association of Pharmaceutical Scientists - 2010 Annual Meeting & Exposition (see PSWC).2010;
Medical condition
Drug Interactions
Product
rosiglitazone
Collaborators
Not applicable
Study date(s)
August 2009 to August 2011
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
20 - 50 years
Accepts healthy volunteers
Yes
- Healthy as determined by a responsible physician
- Subjects are not poor metabolizers based on genotyping for the major CYP2C9, 2C19, 2D6 alleles
- As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unfit for the study.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days (14 days if the drug is a potential enzyme inducer, such as Panaz ginseng, Gingko biloba or St. John’s Wort [Hypericum perforatum]) or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal medications include, but are not limited to: traditional Chinese, Korean and Japanese medicines, Panaz ginseng, Gingko biloba or St John’s wort (Hypericum perforatum) or any Traditional Chinese herbal medicines (TCM) South Asian Ayurvedic medicine, Traditional Korean Medicines and Japanese Kampo.
Inclusion and exclusion criteria
Inclusion criteria:
- Healthy as determined by a responsible physician
- Subjects are not poor metabolizers based on genotyping for the major CYP2C9, 2C19, 2D6 alleles
- Male or female between 20 and 50 years of age at the time of screening, inclusive.
- A female subject is eligible to participate if she is of Non-childbearing potential or postmenopausal
- Body weight greater than or equal to 45 kg and BMI within the range 18.5 to 24.9 kg/m2 (inclusive).
- QTc < 450 msec
- Capable of giving written informed consent
- Able to understand and comply with protocol requirements
Exclusion criteria:
- As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unfit for the study.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days (14 days if the drug is a potential enzyme inducer, such as Panaz ginseng, Gingko biloba or St. John’s Wort [Hypericum perforatum]) or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal medications include, but are not limited to: traditional Chinese, Korean and Japanese medicines, Panaz ginseng, Gingko biloba or St John’s wort (Hypericum perforatum) or any Traditional Chinese herbal medicines (TCM) South Asian Ayurvedic medicine, Traditional Korean Medicines and Japanese Kampo.
- Use of caffeine- or theobromine-containing beverages and foods, or alcohol-containing beverages within 72 hours prior to dosing
- Consumption of the following foods or drinks within 72 hrs prior to dosing : red wine, Seville oranges, grapefruits, pommelos, cruciferous vegetables (e.g., broccoli, Brussels sprouts, cabbage, celery), char-grilled meats, grapefruit juice.
- The subject has a positive pre-study drug/alcohol screen
- Urinary cotinine levels indicative of current smoking or history of regular use of tobacco- or nicotine-containing products within two months prior to screening.
- A positive Hepatitis B surface antigen or positive Hepatitis C antibody at screening.
- A positive test for HIV antibody
- History of regular alcohol consumption within 6 months of the study
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, five half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Systolic blood pressure outside the range of 80 to 140 mmHg, without antihypertensive therapy and no history of hypertension or diastolic blood pressure outside the range of 60 to 85 mmHg, or heart rate outside the range of 50 to 100 beats per minute (bpm) for female and 45 to 100 beats per minute (bpm) for male subjects
- History of syncope or vaso-vagal attacks.
- Pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic or renal function, that could interfere with the absorption, metabolism, or excretion of the study drugs.
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Has a known intolerance or hypersensitivity to aspirin, NSAIDS, or benzodiazepines, or a known intolerance to the active and/or inactive ingredients in omeprazole, dextromethorphan, caffeine, rosiglitazone, pioglitazone, midazolam, rosuvastatin, flurbiprofen, ketoconazole, fluconazole, rifampin, quinidine, gemfibrozil, and fluvoxamine.
- Has any condition or symptom contraindicated for administration of the probe compounds or inhibitors
- History of sensitivity to heparin or heparin-induced thrombocytopenia (if heparin is used to maintain the patency of an intravenous cannula).
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- EGG abnormalities
- Pregnant females or lactating females.
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2011-29-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 112684 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website